Cancer Stem Cells in Multiple Myeloma

Flow Cytometric Definition and Prognostic Effects of Multiple Myeloma Cancer Stem Cells

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01820546

Enrollment

Registered

2013-03-28

Start date

2013-01-31

Completion date

2016-01-31

Last updated

2016-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

In multiple myeloma cancer stem cells can be defined and quantified with flow cytometry. More, these cells can be related to treatment response.

Detailed description

The investigators' hypothesis is that, multiple myeloma plasma cells derivate from principal cells that is called cancer or progenitor stem cell. In multiple myeloma to define immunophenotyping features of these cancer stem cells with flow cytometry and to show their prognostic value and check for any relationship between cancer stem cell quantification and chemotherapy response are main aims of this study.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* New Diagnosed or Relapsed Multiple Myeloma * Routine Bone Marrow Aspiration will be done

Exclusion criteria

* Bone Marrow Aspiration is not Needed

Design outcomes

Primary

Measure	Time frame	Description
Treatment Response	3 months	After 3 courses chemotherapy treatment response

Secondary

Measure	Time frame	Description
Treatment Response	6 months	After 6 courses chemotherapy treatment response

Countries

Turkey (Türkiye)

Outcome results